Teh Seng Pharmaceutical Mfg Co (ROCO:7860) Operating Income: NT$70.6 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7860 Teh Seng Pharmaceutical Mfg Co Ltd ROCO:7860
30 GF Score
Price NT$66.90
! 5 Warning Signs
View Full Analysis

What is Teh Seng Pharmaceutical Mfg Co Operating Income?

Teh Seng Pharmaceutical Mfg Co ROCO:7860 -4.43% 30 Operating Income is NT$70.6 Mil as of Jun. 2026. GuruFocus rates ROCO:7860 with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Teh Seng Pharmaceutical Mfg Co's Operating Income for the six months ended in Jun. 2026 was NT$14.0 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$70.6 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Teh Seng Pharmaceutical Mfg Co's Operating Income for the six months ended in Jun. 2026 was NT$14.0 Mil. Teh Seng Pharmaceutical Mfg Co's Revenue for the six months ended in Jun. 2026 was NT$346.6 Mil. Therefore, Teh Seng Pharmaceutical Mfg Co's Operating Margin % for the quarter that ended in Jun. 2026 was 4.04%.

Teh Seng Pharmaceutical Mfg Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Teh Seng Pharmaceutical Mfg Co's annualized ROC % for the quarter that ended in Jun. 2026 was 2.33%. Teh Seng Pharmaceutical Mfg Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.82%.

Teh Seng Pharmaceutical Mfg Co  (ROCO:7860) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Teh Seng Pharmaceutical Mfg Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=28.012 * ( 1 - 24.03% )/( (898.775 + 930.701)/ 2 )
=21.2807164/914.738
=2.33 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1403.371 - 97.444 - ( 407.152 - max(0, 282.195 - 698.219+407.152))
=898.775

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1355.161 - 92.869 - ( 331.591 - max(0, 309.977 - 650.379+331.591))
=930.701

Note: The Operating Income data used here is two times the semi-annual (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Teh Seng Pharmaceutical Mfg Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=54.152/( ( (666.457 + max(118.22, 0)) + (666.425 + max(136.854, 0)) )/ 2 )
=54.152/( ( 784.677 + 803.279 )/ 2 )
=54.152/793.978
=6.82 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(101.446 + 159.355 + 4.4460000000001) - (97.444 + 0 + 49.583)
=118.22

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(108.65 + 167.451 + 10.2) - (92.869 + 0 + 56.578)
=136.854

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Teh Seng Pharmaceutical Mfg Co's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=14.006/346.624
=4.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Teh Seng Pharmaceutical Mfg Co Operating Income Related Terms

Teh Seng Pharmaceutical Mfg Co Operating Income Historical Data

* Premium members only.

The historical data trend for Teh Seng Pharmaceutical Mfg Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teh Seng Pharmaceutical Mfg Co Operating Income Chart

Teh Seng Pharmaceutical Mfg Co Annual Data
Trend Dec23 Dec24 Dec25
Operating Income
124.49 189.20 140.72

Teh Seng Pharmaceutical Mfg Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Operating Income Get a 7-Day Free Trial 66.26 122.94 84.18 56.55 14.01
ROCO:7860
30GF Score
Teh Seng Pharmaceutical Mfg Co Ltd ROCO:7860
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teh Seng Pharmaceutical Mfg Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$70.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of NT$70.6 Mil mean?
Teh Seng Pharmaceutical Mfg Co (ROCO:7860) has a Operating Income of NT$70.6 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Teh Seng Pharmaceutical Mfg Co and its competitors.
Is Teh Seng Pharmaceutical Mfg Co's Operating Income too high?
Teh Seng Pharmaceutical Mfg Co's current Operating Income is NT$70.6 Mil. Overall, Teh Seng Pharmaceutical Mfg Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Teh Seng Pharmaceutical Mfg Co's Operating Income compare to ZTS?
Teh Seng Pharmaceutical Mfg Co's Operating Income of NT$70.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Teh Seng Pharmaceutical Mfg Co and its competitors. Teh Seng Pharmaceutical Mfg Co's current Operating Income is NT$70.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teh Seng Pharmaceutical Mfg Co stock overvalued right now?
Teh Seng Pharmaceutical Mfg Co (ROCO:7860) has a current Operating Income of NT$70.6 Mil. The current Operating Income is NT$70.6 Mil. Teh Seng Pharmaceutical Mfg Co's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Teh Seng Pharmaceutical Mfg Co (ROCO:7860), the current Operating Income is NT$70.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Teh Seng Pharmaceutical Mfg Co Business Description

Address No.42,Huan Gong Road, Yong Kang District, Tainan, TWN, 710001
Teh Seng Pharmaceutical Mfg Co Ltd is engaged in the development and manufacturing of various pain relieving patches, cosmetic patches and biotechnology products. Its products include: Hydrogel Patches, Oil-Based Patches, Hot-Melt Patches, CMO & CRO for Transdermal Patch, Oral Film & Sublingual, Cosmetic Patches, Biotechnology Products and Daily Supplements.
30GF Score

Get the complete analysis for ROCO:7860

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$66.90
Price